{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T18:57:18Z","timestamp":1771268238773,"version":"3.50.1"},"reference-count":127,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"name":"DST-FIST","award":["SR\/FST\/LS-I\/2018\/131"],"award-info":[{"award-number":["SR\/FST\/LS-I\/2018\/131"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.lfs.2020.117956","type":"journal-article","created":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T04:32:38Z","timestamp":1591936358000},"page":"117956","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":79,"special_numbering":"C","title":["Vaccination strategies to combat novel corona virus SARS-CoV-2"],"prefix":"10.1016","volume":"256","author":[{"given":"Satish Chandra","family":"Pandey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veni","family":"Pande","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diksha","family":"Sati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shobha","family":"Upreti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mukesh","family":"Samant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lfs.2020.117956_bb0010","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ijid.2020.01.009","article-title":"The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health-the latest 2019 novel coronavirus outbreak in Wuhan, China","volume":"91","author":"Hui","year":"2020","journal-title":"Int. J. Infect. Dis."},{"issue":"8","key":"10.1016\/j.lfs.2020.117956_bb0015","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2020.117956_bb0020","series-title":"Another Decade, Another Coronavirus","author":"Perlman","year":"2020"},{"key":"10.1016\/j.lfs.2020.117956_bb0025","series-title":"The Guardian","first-page":"18","article-title":"When will a coronavirus vaccine be ready?","author":"Spinney","year":"2020"},{"issue":"11","key":"10.1016\/j.lfs.2020.117956_bb0030","doi-asserted-by":"crossref","DOI":"10.1097\/01.inf.0000188166.17324.60","article-title":"History and recent advances in coronavirus discovery","volume":"24","author":"Kahn","year":"2005","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.lfs.2020.117956_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4939-2438-7_1","article-title":"Coronaviruses: an overview of their replication and pathogenesis","volume":"1282","author":"Fehr","year":"2015","journal-title":"Methods Mol. Biol."},{"issue":"2","key":"10.1016\/j.lfs.2020.117956_bb0040","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1073\/pnas.0805270106","article-title":"Cryo-electron tomography of mouse hepatitis virus: insights into the structure of the coronavirion","volume":"106","author":"B\u00e1rcena","year":"2009","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"16","key":"10.1016\/j.lfs.2020.117956_bb0045","doi-asserted-by":"crossref","first-page":"7918","DOI":"10.1128\/JVI.00645-06","article-title":"Supramolecular architecture of severe acute respiratory syndrome coronavirus revealed by electron cryomicroscopy","volume":"80","author":"Neuman","year":"2006","journal-title":"J. Virol."},{"issue":"18","key":"10.1016\/j.lfs.2020.117956_bb0050","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical Characteristics of Coronavirus Disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2020.117956_bb0055","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1001\/jama.2020.0757","article-title":"Coronavirus infections-more than just the common cold","volume":"323","author":"Paules","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.lfs.2020.117956_bb0060","doi-asserted-by":"crossref","first-page":"643","DOI":"10.20506\/rst.23.2.1513","article-title":"Animal coronaviruses: what can they teach us about the severe acute respiratory syndrome?","volume":"23","author":"Saif","year":"2004","journal-title":"Rev. Sci. Tech."},{"key":"10.1016\/j.lfs.2020.117956_bb0065","doi-asserted-by":"crossref","first-page":"1):1","DOI":"10.1186\/s12916-020-01533-w","article-title":"Q&A: the novel coronavirus outbreak causing COVID-19","volume":"18","author":"Fisher","year":"2020","journal-title":"BMC Med."},{"key":"10.1016\/j.lfs.2020.117956_bb0070","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.3390\/v4061011","article-title":"Mechanisms of coronavirus cell entry mediated by the viral spike protein","volume":"4","author":"Belouzard","year":"2012","journal-title":"Viruses"},{"key":"10.1016\/j.lfs.2020.117956_bb0075","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1111\/febs.12936","article-title":"From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design","volume":"281","author":"Hilgenfeld","year":"2014","journal-title":"FEBS J."},{"key":"10.1016\/j.lfs.2020.117956_bb0080","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2217\/fvl-2018-0144","article-title":"Membrane binding proteins of coronaviruses","volume":"14","author":"Alsaadi","year":"2019","journal-title":"Futur. Virol."},{"issue":"7","key":"10.1016\/j.lfs.2020.117956_bb0085","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1586\/erv.09.43","article-title":"SARS vaccines: where are we?","volume":"8","author":"Roper","year":"2009","journal-title":"Expert Review of Vaccines"},{"issue":"4","key":"10.1016\/j.lfs.2020.117956_bb0090","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1128\/JVI.77.4.2530-2538.2003","article-title":"Identification of a receptor-binding domain of the spike glycoprotein of human coronavirus HCoV-229E","volume":"77","author":"Bonavia","year":"2003","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.lfs.2020.117956_bb0095","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/path.1769","article-title":"An animal model of SARS produced by infection of Macaca mulatta with SARS coronavirus","volume":"206","author":"Qin","year":"2005","journal-title":"The Journal of Pathology: A Journal of the Pathological Society of Great Britain and Ireland"},{"issue":"26","key":"10.1016\/j.lfs.2020.117956_bb0100","doi-asserted-by":"crossref","first-page":"5498","DOI":"10.1016\/j.vaccine.2006.04.054","article-title":"Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein: revealing the critical antigenic determinants in inactivated SARS-CoV vaccine","volume":"24","author":"He","year":"2006","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.lfs.2020.117956_bb0105","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1128\/JVI.02055-12","article-title":"Comparative analysis of simian immunodeficiency virus gag-specific effector and memory CD8+ T cells induced by different adenovirus vectors","volume":"87","author":"Tan","year":"2013","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.lfs.2020.117956_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/imm.12829","article-title":"Novel viral vectors in infectious diseases","volume":"153","author":"Humphreys","year":"2018","journal-title":"Immunology"},{"issue":"3","key":"10.1016\/j.lfs.2020.117956_bb0115","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1586\/14760584.2016.1124762","article-title":"Molecular mechanisms for enhanced DNA vaccine immunogenicity","volume":"15","author":"Li","year":"2016","journal-title":"Expert Review of Vaccines"},{"issue":"6982","key":"10.1016\/j.lfs.2020.117956_bb0120","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature02463","article-title":"A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice","volume":"428","author":"Yang","year":"2004","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.lfs.2020.117956_bb0125","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/iub.1625","article-title":"RNA sensors of the innate immune system and their detection of pathogens","volume":"69","author":"Chen","year":"2017","journal-title":"IUBMB Life"},{"issue":"1","key":"10.1016\/j.lfs.2020.117956_bb0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-016-1111-6","article-title":"Adjuvant effects of a sequence-engineered mRNA vaccine: translational profiling demonstrates similar human and murine innate response","volume":"15","author":"Edwards","year":"2017","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.lfs.2020.117956_bb0135","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/s12967-016-0927-4","article-title":"Exosomes in the nose induce immune cell trafficking and harbour an altered protein cargo in chronic airway inflammation","volume":"14","author":"L\u00e4sser","year":"2016","journal-title":"J. Transl. Med."},{"issue":"39","key":"10.1016\/j.lfs.2020.117956_bb0140","doi-asserted-by":"crossref","first-page":"14040","DOI":"10.1073\/pnas.0506735102","article-title":"Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats","volume":"103","author":"Lau","year":"2005","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"15","key":"10.1016\/j.lfs.2020.117956_bb0145","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1056\/NEJMoa1404505","article-title":"Emergence of Zaire Ebola virus disease in Guinea","volume":"371","author":"Baize","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.lfs.2020.117956_bb0150","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/jmv.1890060309","article-title":"Coronavirus infections of man associated with diseases other than the common cold","volume":"6","author":"Riski","year":"1980","journal-title":"J. Med. Virol."},{"issue":"2","key":"10.1016\/j.lfs.2020.117956_bb0155","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1128\/CMR.00102-14","article-title":"Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease","volume":"28","author":"Chan","year":"2015","journal-title":"Clin. Microbiol. Rev."},{"issue":"2","key":"10.1016\/j.lfs.2020.117956_bb0160","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2174\/1573395054065106","article-title":"Rapid response research - SARS coronavirus vaccines and application of processes to other emerging infectious diseases","volume":"1","author":"See","year":"2005","journal-title":"Curr. Immunol. Rev."},{"issue":"1","key":"10.1016\/j.lfs.2020.117956_bb0165","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1086\/515613","article-title":"First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response","volume":"178","author":"MacGregor","year":"1998","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.lfs.2020.117956_bb0170","article-title":"Human immunodeficiency virus vaccine trials","volume":"2","author":"O\u2019Connell","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.lfs.2020.117956_bb0175","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1093\/cid\/cir334","article-title":"Clinical applications of DNA vaccines: current progress","volume":"53","author":"Ferraro","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.lfs.2020.117956_bb0180","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1146\/annurev.immunol.18.1.927","article-title":"DNA vaccines: immunology, application, and optimization","volume":"18","author":"Gurunathan","year":"2000","journal-title":"Annu. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.lfs.2020.117956_bb0185","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.bbrc.2004.01.166","article-title":"Characterization of humoral responses in mice immunized with plasmid DNAs encoding SARS-CoV spike gene fragments","volume":"315","author":"Zeng","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"10","key":"10.1016\/j.lfs.2020.117956_bb0190","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1089\/dna.2007.0616","article-title":"Optimization of a DNA vaccine against SARS","volume":"26","author":"Zakhartchouk","year":"2007","journal-title":"DNA Cell Biol."},{"issue":"2","key":"10.1016\/j.lfs.2020.117956_bb0195","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.virol.2007.01.012","article-title":"Heterologous viral RNA export elements improve expression of severe acute respiratory syndrome (SARS) coronavirus spike protein and protective efficacy of DNA vaccines against SARS","volume":"363","author":"Callendret","year":"2007","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.lfs.2020.117956_bb0200","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.bbrc.2004.11.147","article-title":"Immune responses with DNA vaccines encoded different gene fragments of severe acute respiratory syndrome coronavirus in BALB\/c mice","volume":"327","author":"Wang","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1\u20132","key":"10.1016\/j.lfs.2020.117956_bb0205","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.imlet.2008.04.005","article-title":"A chimeric multi-epitope DNA vaccine elicited specific antibody response against severe acute respiratory syndrome-associated coronavirus which attenuated the virulence of SARS-CoV in vitro","volume":"119","author":"Wang","year":"2008","journal-title":"Immunol. Lett."},{"issue":"3","key":"10.1016\/j.lfs.2020.117956_bb0210","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.imlet.2004.01.001","article-title":"Induction of SARS-nucleoprotein-specific immune response by use of DNA vaccine","volume":"92","author":"Zhu","year":"2004","journal-title":"Immunol. Lett."},{"issue":"9","key":"10.1016\/j.lfs.2020.117956_bb0215","doi-asserted-by":"crossref","first-page":"4638","DOI":"10.1128\/JVI.78.9.4638-4645.2004","article-title":"Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome coronavirus","volume":"78","author":"Kim","year":"2004","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.lfs.2020.117956_bb0220","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.virol.2004.10.016","article-title":"Immune responses against SARS-coronavirus nucleocapsid protein induced by DNA vaccine","volume":"331","author":"Zhao","year":"2005","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.lfs.2020.117956_bb0225","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.virol.2005.11.042","article-title":"SARS coronavirus nucleocapsid immunodominant T-cell epitope cluster is common to both exogenous recombinant and endogenous DNA-encoded immunogens","volume":"347","author":"Gupta","year":"2006","journal-title":"Virology"},{"issue":"32","key":"10.1016\/j.lfs.2020.117956_bb0230","doi-asserted-by":"crossref","first-page":"6070","DOI":"10.1016\/j.vaccine.2007.05.025","article-title":"Induction of T-cell response by a DNA vaccine encoding a novel HLA-A* 0201 severe acute respiratory syndrome coronavirus epitope","volume":"25","author":"Cheung","year":"2007","journal-title":"Vaccine"},{"issue":"16","key":"10.1016\/j.lfs.2020.117956_bb0235","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1016\/j.vaccine.2007.01.032","article-title":"Development of vaccines and passive immunotherapy against SARS corona virus using SCID-PBL\/hu mouse models","volume":"25","author":"Okada","year":"2007","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.lfs.2020.117956_bb0240","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.virusres.2007.03.025","article-title":"Animal models and vaccines for SARS-CoV infection","volume":"133","author":"Roberts","year":"2008","journal-title":"Virus Res."},{"issue":"39\u201340","key":"10.1016\/j.lfs.2020.117956_bb0245","doi-asserted-by":"crossref","first-page":"6981","DOI":"10.1016\/j.vaccine.2007.06.047","article-title":"Priming with SARS CoV S DNA and boosting with SARS CoV S epitopes specific for CD4+ and CD8+ T cells promote cellular immune responses","volume":"25","author":"Huang","year":"2007","journal-title":"Vaccine"},{"issue":"35","key":"10.1016\/j.lfs.2020.117956_bb0250","doi-asserted-by":"crossref","first-page":"4385","DOI":"10.1016\/j.vaccine.2005.04.011","article-title":"Augmentation of immune responses to SARS coronavirus by a combination of DNA and whole killed virus vaccines","volume":"23","author":"Zakhartchouk","year":"2005","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.lfs.2020.117956_bb0255","first-page":"459","article-title":"Comparative immunization in BALB\/c mice with recombinant replication-defective adenovirus vector and DNA plasmid expressing a SARS-CoV nucleocapsid protein gene","volume":"3","author":"Ma","year":"2006","journal-title":"Cell. Mol. Immunol."},{"issue":"4","key":"10.1016\/j.lfs.2020.117956_bb0260","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines-a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.lfs.2020.117956_bb0285","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1146\/annurev-virology-110615-042301","article-title":"Structure, function, and evolution of coronavirus spike proteins","volume":"3","author":"Li","year":"2016","journal-title":"Annu. Rev. Virol."},{"issue":"153","key":"10.1016\/j.lfs.2020.117956_bb0290","article-title":"Progress and Prospects on Vaccine Development against SARS-CoV-2","volume":"8","author":"Zhang","year":"2020","journal-title":"Vaccines"},{"issue":"6965","key":"10.1016\/j.lfs.2020.117956_bb0295","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/nature02145","article-title":"Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus","volume":"426","author":"Li","year":"2003","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.lfs.2020.117956_bb0300","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jcv.2003.09.011","article-title":"Severe acute respiratory syndrome (SARS) - paradigm of an emerging viral infection","volume":"29","author":"Berger","year":"2004","journal-title":"J. Clin. Virol."},{"issue":"6","key":"10.1016\/j.lfs.2020.117956_bb0305","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.4049\/jimmunol.173.6.4050","article-title":"Identification of immunodominant sites on the spike protein of severe acute respiratory syndrome (SARS) coronavirus: implication for developing SARS diagnostics and vaccines","volume":"173","author":"He","year":"2004","journal-title":"J. Immunol."},{"issue":"22","key":"10.1016\/j.lfs.2020.117956_bb0310","doi-asserted-by":"crossref","first-page":"12672","DOI":"10.1128\/JVI.78.22.12672-12676.2004","article-title":"Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets","volume":"78","author":"Weingartl","year":"2004","journal-title":"J. Virol."},{"issue":"17","key":"10.1016\/j.lfs.2020.117956_bb0315","doi-asserted-by":"crossref","first-page":"6641","DOI":"10.1073\/pnas.0401939101","article-title":"Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice","volume":"101","author":"Bisht","year":"2004","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"2","key":"10.1016\/j.lfs.2020.117956_bb0320","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1089\/vim.2012.0076","article-title":"Immunogenicity and protection efficacy of monomeric and trimeric recombinant SARS coronavirus spike protein subunit vaccine candidates","volume":"26","author":"Li","year":"2013","journal-title":"Viral Immunol."},{"issue":"2","key":"10.1016\/j.lfs.2020.117956_bb0325","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.bbrc.2004.10.052","article-title":"Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry","volume":"325","author":"He","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.lfs.2020.117956_bb0330","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.virol.2005.01.034","article-title":"Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines","volume":"334","author":"He","year":"2005","journal-title":"Virology"},{"issue":"2","key":"10.1016\/j.lfs.2020.117956_bb0335","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.bbrc.2004.09.106","article-title":"Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine","volume":"342","author":"He","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"3","key":"10.1016\/j.lfs.2020.117956_bb0340","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1128\/JVI.79.3.1906-1910.2005","article-title":"Identification of two neutralizing regions on the severe acute respiratory syndrome coronavirus spike glycoprotein produced from the mammalian expression system","volume":"79","author":"Wang","year":"2005","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.lfs.2020.117956_bb0345","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.virol.2004.04.017","article-title":"SARS corona virus peptides recognized by antibodies in the sera of convalescent cases","volume":"324","author":"Guo","year":"2004","journal-title":"Virology"},{"issue":"10","key":"10.1016\/j.lfs.2020.117956_bb0350","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1099\/vir.0.80111-0","article-title":"Protective humoral responses to severe acute respiratory syndrome-associated coronavirus: implications for the design of an effective protein-based vaccine","volume":"85","author":"Pang","year":"2004","journal-title":"J. Gen. Virol."},{"issue":"1","key":"10.1016\/j.lfs.2020.117956_bb0355","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12985-019-1182-0","article-title":"Coronavirus envelope protein: current knowledge","volume":"16","author":"Schoeman","year":"2019","journal-title":"Virol. J."},{"key":"10.1016\/j.lfs.2020.117956_bb0360","series-title":"Coronavirus Structural Proteins and Virus Assembly","author":"Hogue","year":"2008"},{"issue":"1\u20132","key":"10.1016\/j.lfs.2020.117956_bb0365","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0378-1135(93)90126-R","article-title":"A review of feline infectious peritonitis virus: molecular biology, immunopathogenesis, clinical aspects, and vaccination","volume":"36","author":"Olsen","year":"1993","journal-title":"Vet. Microbiol."},{"issue":"2","key":"10.1016\/j.lfs.2020.117956_bb0370","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1128\/jvi.69.2.684-694.1995","article-title":"Mouse hepatitis virus-specific cytotoxic T lymphocytes protect from lethal infection without eliminating virus from the central nervous system","volume":"69","author":"Stohlman","year":"1995","journal-title":"J. Virol."},{"issue":"12","key":"10.1016\/j.lfs.2020.117956_bb0375","doi-asserted-by":"crossref","first-page":"7050","DOI":"10.1128\/jvi.67.12.7050-7059.1993","article-title":"Characterization of mouse hepatitis virus-specific cytotoxic T cells derived from the central nervous system of mice infected with the JHM strain","volume":"67","author":"Stohlman","year":"1993","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.lfs.2020.117956_bb0380","first-page":"8","article-title":"Localization of a T-cell epitope within the nucleocapsid protein of avian coronavirus","volume":"74","author":"Boots","year":"1991","journal-title":"Immunol. Lett."},{"issue":"2\u20133","key":"10.1016\/j.lfs.2020.117956_bb0385","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0145-305X(99)00072-5","article-title":"Cytotoxic T lymphocytes are critical in the control of infectious bronchitis virus in poultry","volume":"24","author":"Collisson","year":"2000","journal-title":"Dev. Comp. Immunol."},{"key":"10.1016\/j.lfs.2020.117956_bb0390","series-title":"Development of Protection Against Coronavirus Induced Diseases","author":"Enjuanes","year":"1995"},{"issue":"36","key":"10.1016\/j.lfs.2020.117956_bb0395","doi-asserted-by":"crossref","first-page":"5001","DOI":"10.1016\/j.vaccine.2009.05.073","article-title":"Boosted expression of the SARS-CoV nucleocapsid protein in tobacco and its immunogenicity in mice","volume":"27","author":"Zheng","year":"2009","journal-title":"Vaccine"},{"issue":"16","key":"10.1016\/j.lfs.2020.117956_bb0400","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1016\/j.vaccine.2006.01.058","article-title":"Immunological characterizations of the nucleocapsid protein based SARS vaccine candidates","volume":"24","author":"Liu","year":"2006","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.lfs.2020.117956_bb0405","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3390\/v12020135","article-title":"Return of the coronavirus: 2019-nCoV","volume":"12","author":"Gralinski","year":"2020","journal-title":"Viruses"},{"issue":"7","key":"10.1016\/j.lfs.2020.117956_bb0410","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1006857","article-title":"Recombinant vector vaccine evolution","volume":"15","author":"Bull","year":"2019","journal-title":"PLoS Comput. Biol."},{"issue":"2","key":"10.1016\/j.lfs.2020.117956_bb0415","first-page":"83","article-title":"Recombinant viruses as tools to induce protective cellular immunity against infectious diseases","volume":"7","author":"Rocha","year":"2004","journal-title":"Int. Microbiol."},{"issue":"1","key":"10.1016\/j.lfs.2020.117956_bb0420","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1099\/vir.0.80530-0","article-title":"Severe acute respiratory syndrome coronavirus nucleocapsid protein expressed by an adenovirus vector is phosphorylated and immunogenic in mice","volume":"86","author":"Zakhartchouk","year":"2005","journal-title":"J. Gen. Virol."},{"issue":"4","key":"10.1016\/j.lfs.2020.117956_bb0425","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0952-7915(97)80104-5","article-title":"Recombinant viruses as vaccines and immunological tools","volume":"9","author":"Rolph","year":"1997","journal-title":"Curr. Opin. Immunol."},{"issue":"9399","key":"10.1016\/j.lfs.2020.117956_bb0430","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/S0140-6736(03)14962-8","article-title":"Effects of a SARS-associated coronavirus vaccine in monkeys","volume":"362","author":"Gao","year":"2003","journal-title":"Lancet"},{"issue":"Pt 3","key":"10.1016\/j.lfs.2020.117956_bb0435","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1099\/vir.0.81579-0","article-title":"Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus","volume":"87","author":"See","year":"2006","journal-title":"J. Gen. Virol."},{"issue":"1","key":"10.1016\/j.lfs.2020.117956_bb0440","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.virol.2007.12.032","article-title":"The SARS-CoV ferret model in an infection\u2013challenge study","volume":"374","author":"Chu","year":"2008","journal-title":"Virology"},{"issue":"Pt 9","key":"10.1016\/j.lfs.2020.117956_bb0445","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1099\/vir.0.2008\/001891-0","article-title":"Severe acute respiratory syndrome vaccine efficacy in ferrets: whole killed virus and adenovirus-vectored vaccines","volume":"89","author":"See","year":"2008","journal-title":"J. Gen. Virol."},{"issue":"28","key":"10.1016\/j.lfs.2020.117956_bb0450","doi-asserted-by":"crossref","first-page":"5220","DOI":"10.1016\/j.vaccine.2007.04.065","article-title":"Adenovirus-based vaccine prevents pneumonia in ferrets challenged with the SARS coronavirus and stimulates robust immune responses in macaques","volume":"25","author":"Kobinger","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.lfs.2020.117956_bb0455","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0040385","article-title":"A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity","volume":"7","author":"Dicks","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2020.117956_bb0460","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.3389\/fmicb.2019.01781","article-title":"Recent advances in the vaccine development against Middle East respiratory syndrome-coronavirus","volume":"10","author":"Yong","year":"2019","journal-title":"Front. Microbiol."},{"issue":"13","key":"10.1016\/j.lfs.2020.117956_bb0465","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/0264-410X(95)00032-V","article-title":"Adenovirus vectors as recombinant viral vaccines","volume":"13","author":"Imler","year":"1995","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.lfs.2020.117956_bb0470","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.4161\/hv.29594","article-title":"Pre-existing immunity against ad vectors: humoral, cellular, and innate response, what\u2019s important?","volume":"10","author":"Fausther-Bovendo","year":"2014","journal-title":"Human Vaccines & Immunotherapeutics"},{"issue":"21","key":"10.1016\/j.lfs.2020.117956_bb0475","doi-asserted-by":"crossref","first-page":"11950","DOI":"10.1128\/JVI.01672-13","article-title":"Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies","volume":"87","author":"Song","year":"2013","journal-title":"Journal of virology"},{"issue":"16","key":"10.1016\/j.lfs.2020.117956_bb0480","doi-asserted-by":"crossref","first-page":"8651","DOI":"10.1128\/JVI.00614-15","article-title":"Protective efficacy of recombinant modified vaccinia virus Ankara delivering Middle East respiratory syndrome coronavirus spike glycoprotein","volume":"89","author":"Volz","year":"2015","journal-title":"Journal of virology"},{"issue":"30","key":"10.1016\/j.lfs.2020.117956_bb0485","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1016\/j.vaccine.2017.05.032","article-title":"ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice","volume":"35","author":"Alharbi","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.lfs.2020.117956_bb0490","series-title":"Safety, Tolerability and Immunogenicity of Vaccine Candidate MVA-MERS-S","author":"Health NIo","year":"2018"},{"issue":"12","key":"10.1016\/j.lfs.2020.117956_bb0495","doi-asserted-by":"crossref","first-page":"718","DOI":"10.3390\/v10120718","article-title":"CD8+ T cells responding to the middle east respiratory syndrome coronavirus nucleocapsid protein delivered by vaccinia virus MVA in mice","volume":"10","author":"Veit","year":"2018","journal-title":"Viruses"},{"key":"10.1016\/j.lfs.2020.117956_bb0500","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.antiviral.2017.12.007","article-title":"A recombinant VSV-vectored MERS-CoV vaccine induces neutralizing antibody and T cell responses in rhesus monkeys after single dose immunization","volume":"150","author":"Liu","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.lfs.2020.117956_bb0505","doi-asserted-by":"crossref","first-page":"624","DOI":"10.3390\/vaccines2030624","article-title":"Developments in viral vector-based vaccines","volume":"2","author":"Ura","year":"2014","journal-title":"Vaccines"},{"issue":"5","key":"10.1016\/j.lfs.2020.117956_bb0510","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.it.2020.03.007","article-title":"Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses","volume":"41","author":"Jiang","year":"2020","journal-title":"Trends Immunol."},{"issue":"34","key":"10.1016\/j.lfs.2020.117956_bb0515","doi-asserted-by":"crossref","first-page":"4709","DOI":"10.1016\/j.vaccine.2009.05.050","article-title":"Efficacy and safety of live attenuated persistent and rapidly cleared Mycobacterium tuberculosis vaccine candidates in non-human primates","volume":"27","author":"Larsen","year":"2007","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.lfs.2020.117956_bb0520","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0168-1702(89)90018-X","article-title":"Rubella virus: mechanism of attenuation in the vaccine strain (HPV77)","volume":"13","author":"Nakhasi","year":"1989","journal-title":"Virus Res."},{"issue":"1\u20132","key":"10.1016\/j.lfs.2020.117956_bb0525","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/BF01311044","article-title":"Vaccinia virus: a suitable vehicle for recombinant vaccines?","volume":"106","author":"Kaplan","year":"1989","journal-title":"Arch. Virol."},{"issue":"1","key":"10.1016\/j.lfs.2020.117956_bb0530","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1128\/JVI.01532-15","article-title":"Sabin vaccine reversion in the field: a comprehensive analysis of Sabin-like poliovirus isolates in Nigeria","volume":"90","author":"Famulare","year":"2015","journal-title":"J. Virol."},{"issue":"4","key":"10.1016\/j.lfs.2020.117956_bb0535","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1128\/JVI.01467-06","article-title":"A severe acute respiratory syndrome coronavirus that lacks the E gene is attenuated in vitro and in vivo","volume":"81","author":"DeDiego","year":"2007","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.lfs.2020.117956_bb0540","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.virol.2008.03.005","article-title":"Pathogenicity of severe acute respiratory coronavirus deletion mutants in hACE-2 transgenic mice","volume":"376","author":"DeDiego","year":"2008","journal-title":"Virology"},{"issue":"15","key":"10.1016\/j.lfs.2020.117956_bb0545","doi-asserted-by":"crossref","first-page":"7721","DOI":"10.1128\/JVI.00304-08","article-title":"A live attenuated severe acute respiratory syndrome coronavirus is immunogenic and efficacious in golden Syrian hamsters","volume":"82","author":"Lamirande","year":"2008","journal-title":"J. Virol."},{"issue":"8","key":"10.1016\/j.lfs.2020.117956_bb0550","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1371\/journal.ppat.0030109","article-title":"Coronavirus non-structural protein 1 is a major pathogenicity factor: implications for the rational design of coronavirus vaccines","volume":"3","author":"Z\u00fcst","year":"2007","journal-title":"PLoS Pathog."},{"issue":"23","key":"10.1016\/j.lfs.2020.117956_bb0555","doi-asserted-by":"crossref","first-page":"14909","DOI":"10.1128\/JVI.79.23.14909-14922.2005","article-title":"Severe acute respiratory syndrome coronavirus group-specific open reading frames encode nonessential functions for replication in cell cultures and mice","volume":"79","author":"Yount","year":"2005","journal-title":"J. Virol."},{"issue":"4","key":"10.1016\/j.lfs.2020.117956_bb0560","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.immuni.2020.03.007","article-title":"SARS-CoV-2 vaccines: status report","volume":"52","author":"Amanat","year":"2020","journal-title":"Immunity"},{"issue":"34","key":"10.1016\/j.lfs.2020.117956_bb0565","doi-asserted-by":"crossref","first-page":"12885","DOI":"10.1073\/pnas.0603144103","article-title":"Severe acute respiratory syndrome coronavirus nsp1 protein suppresses host gene expression by promoting host mRNA degradation","volume":"103","author":"Kamitani","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"5","key":"10.1016\/j.lfs.2020.117956_bb0570","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1128\/JVI.79.5.3182-3186.2005","article-title":"Severe acute respiratory syndrome coronavirus 3a protein is a viral structural protein","volume":"79","author":"Ito","year":"2005","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.lfs.2020.117956_bb0575","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1128\/JVI.01691-06","article-title":"The ORF7b protein of severe acute respiratory syndrome coronavirus (SARS-CoV) is expressed in virus-infected cells and incorporated into SARS-CoV particles","volume":"81","author":"Schaecher","year":"2007","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.lfs.2020.117956_bb0580","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.bbrc.2005.02.153","article-title":"The severe acute respiratory syndrome coronavirus 3a is a novel structural protein","volume":"330","author":"Shen","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"2","key":"10.1016\/j.lfs.2020.117956_bb0585","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.imlet.2004.06.014","article-title":"Immunogenicity of SARS inactivated vaccine in BALB\/c mice","volume":"95","author":"Xiong","year":"2004","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.lfs.2020.117956_bb0590","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/978-1-59745-181-9_11","article-title":"Large-scale preparation of UV-inactivated SARS coronavirus virions for vaccine antigen","volume":"454","author":"Tsunetsugu-Yokota","year":"2008","journal-title":"Methods Mol. Biol."},{"issue":"10","key":"10.1016\/j.lfs.2020.117956_bb0595","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1093\/intimm\/dxh143","article-title":"A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice","volume":"16","author":"Takasuka","year":"2004","journal-title":"Int. Immunol."},{"issue":"6","key":"10.1016\/j.lfs.2020.117956_bb0600","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1089\/104454904323145272","article-title":"Inactivated SARS-CoV vaccine prepared from whole virus induces a high level of neutralizing antibodies in BALB\/c mice","volume":"23","author":"Tang","year":"2004","journal-title":"DNA Cell Biol."},{"issue":"7","key":"10.1016\/j.lfs.2020.117956_bb0605","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.vaccine.2004.07.031","article-title":"Intranasal immunization with inactivated SARS-CoV (SARS-associated coronavirus) induced local and serum antibodies in mice","volume":"23","author":"Qu","year":"2005","journal-title":"Vaccine"},{"issue":"24","key":"10.1016\/j.lfs.2020.117956_bb0610","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1016\/j.vaccine.2004.11.073","article-title":"Immune responses in Balb\/c mice induced by a candidate SARS-CoV inactivated vaccine prepared from F69 strain","volume":"23","author":"Zhang","year":"2005","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.lfs.2020.117956_bb0615","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.3201\/eid1108.041003","article-title":"SARS vaccine protective in mice","volume":"11","author":"Stadler","year":"2005","journal-title":"Emerg. Infect. Dis."},{"issue":"9","key":"10.1016\/j.lfs.2020.117956_bb0620","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1086\/522431","article-title":"Severe acute respiratory syndrome coronavirus infection in vaccinated ferrets","volume":"196","author":"Darnell","year":"2007","journal-title":"J. Infect. Dis."},{"issue":"24","key":"10.1016\/j.lfs.2020.117956_bb0625","doi-asserted-by":"crossref","first-page":"3202","DOI":"10.1016\/j.vaccine.2004.11.075","article-title":"Immunogenicity, safety, and protective efficacy of an inactivated SARS-associated coronavirus vaccine in rhesus monkeys","volume":"23","author":"Zhou","year":"2005","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.lfs.2020.117956_bb0630","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1177\/135965350701200702","article-title":"Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine","volume":"12","author":"Lin","year":"2007","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.lfs.2020.117956_bb0635","doi-asserted-by":"crossref","DOI":"10.1038\/srep44875","article-title":"Immunogenicity of candidate MERS-CoV DNA vaccines based on the spike protein","volume":"7","author":"Al-Amri","year":"2017","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.lfs.2020.117956_bb0640","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nrmicro2090","article-title":"The spike protein of SARS-CoV-a target for vaccine and therapeutic development","volume":"7","author":"Du","year":"2009","journal-title":"Nat. Rev. Microbiol."},{"issue":"15","key":"10.1016\/j.lfs.2020.117956_bb0645","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1016\/j.vaccine.2006.10.031","article-title":"Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model","volume":"25","author":"Du","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.lfs.2020.117956_bb0650","article-title":"Safety and immunogenicity of an anti-Zika virus DNA vaccine-preliminary report","author":"Tebas","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.lfs.2020.117956_bb0655","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.ymthe.2019.01.020","article-title":"mRNA as a transformative technology for vaccine development to control infectious diseases","volume":"27","author":"Maruggi","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.lfs.2020.117956_bb0660","first-page":"1","article-title":"The SARS-CoV-2 vaccine pipeline: an overview","author":"Chen","year":"2020","journal-title":"Curr. Trop. Med. Rep."}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320520307062?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320520307062?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T19:19:43Z","timestamp":1735413583000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320520307062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":127,"alternative-id":["S0024320520307062"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2020.117956","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vaccination strategies to combat novel corona virus SARS-CoV-2","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2020.117956","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"117956"}}